Earnings Releases·Nov 4, 2026, 4:12 PM ET

Progyny, Inc. — Third Quarter 2026 Earnings Summary

Revenue rose 8.9% year-over-year to $341.3 million, driven by a 10.6% increase in fertility benefit services and a 5.8% rise in pharmacy benefit services, while net income more than doubled to $26.3 million ($0.32 per share) from $13.9 million in the prior year period.
Full-year 2026 revenue guidance was raised to $1.365 billion–$1.385 billion (5.9%–7.5% growth), with adjusted EBITDA projected at $235.0 million–$240.0 million and net income at $107.0 million–$110.6 million.
The company repurchased nearly 3 million shares for $82.7 million in the quarter, bringing total 2026 buybacks to nearly 11 million shares, while maintaining a debt-free balance sheet with $195.6 million in cash and marketable securities.
Operational momentum remains strong with the addition of over 85 new clients and a record 1.3 million new covered lives in the recent selling season, with the majority of these clients expected to go live in Q1 2027.